- ADME toxicology testing, which includes evaluating a drug’s absorption, distribution, metabolism, and excretion properties along with potential toxicity, is becoming increasingly vital across pharmaceutical and biotechnology research in the Asia-Pacific region due to rising drug development activities and regulatory emphasis on early safety profiling
- The escalating demand for ADME toxicology solutions is fueled by the growing prevalence of chronic diseases, increased clinical trial activity, and heightened focus on reducing late-stage drug failures in countries such as China, India, Japan, and South Korea
- China dominated the Asia-Pacific ADME toxicology testing market, with the largest share within Asia-Pacific at 37.8% in 2024. This dominance is attributed to the rapid expansion of China’s pharmaceutical sector, strong government support through initiatives such as “Made in China 2025,” and an increasing number of drug approvals requiring safety evaluations
- India is expected to be the fastest growing region in the Asia-Pacific ADME toxicology testing market with a CAGR of 28.7% from 2025 to 2032. The country’s rapidly growing pharmaceutical manufacturing base, cost-effective R&D ecosystem, and rise in government and private investment in life sciences are key factors driving growth
- In-vitro testing segment dominated the Asia-Pacific ADME toxicology testing market with a market share of 61.4% in 2024, driven by strong regulatory support and reduced ethical concerns compared to animal-based testing. Its growing acceptance as a reliable alternative for toxicity screening and pharmacokinetic studies has positioned it as a preferred method among pharmaceutical and research organizations across the region
